Reference
Research and Regulatory Reference
Reference pages covering regulatory frameworks governing peptide compounding and research access, and research context for topics that span multiple compounds.
FDA / 503A Compounding
FDA Peptide Reclassification 2026
Explains the September 2023 Category 2 restrictions on 19 peptides, the February and April 2026 reclassification under RFK Jr., which compounds were removed from the prohibited list, which remain restricted, and what the change does and does not mean legally and clinically.
Research Context
Peptides and Cancer
Covers two distinct questions: which commonly researched peptides carry cancer risk concerns (TB-500, GH secretagogues, GLP-1 RAs, Melanotan II, BPC-157) and what the evidence shows; and separately, how peptides are being researched as cancer treatments including neoantigen vaccines, checkpoint inhibitors, and targeted drug delivery.
Research Context
Peptides and ADHD
Covers what research exists on peptides in the context of ADHD and attention, including Semax, Selank, Cerebrolysin, Oxytocin, and DSIP. Distinguishes mechanistic rationale from clinical evidence, addresses the gap between anecdotal reports and validated treatment, and covers safety considerations for those already on stimulant medication.
Research Context
Peptides and Pregnancy
Research overview of peptide use during pregnancy, organised by compound class. Covers the explicit FDA and EMA warnings for GLP-1 receptor agonists, the theoretical concerns for GH secretagogues, the data gaps for BPC-157 and TB-500, the PT-141 contraindication, and the complete absence of evidence for longevity and nootropic peptides. Addresses what the evidence gap actually means.